Condition: Gram-negative Bacteremia · Sponsor: Johns Hopkins University
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
This description comes directly from the study's public registry record.
Pranita D Tamma, MD, MHS · 410-614-1492 · tammap1@chop.edu
Sara E Cosgrove, MD, MS · 443-287-4570 · scosgro1@jhmi.edu
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Denver Health Hospital Authority | Denver, Colorado, United States | Recruiting |
| University of Maryland Medical Center | Baltimore, Maryland, United States | Recruiting |
| Johns Hopkins University Hospital Systems | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Rutgers-RWJ University Hospital | New Brunswick, New Jersey, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Houston Methodist | Houston, Texas, United States | Recruiting |
| Carilion Clinic | Roanoke, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06080698